| Literature DB >> 32063999 |
Abstract
Entities:
Keywords: Characteristics; Chinese medicines; NF-κB; Ulcerative colitis
Year: 2020 PMID: 32063999 PMCID: PMC7011253 DOI: 10.1186/s13020-020-0296-z
Source DB: PubMed Journal: Chin Med ISSN: 1749-8546 Impact factor: 5.455
Direct inhibited efficacy of Chinese medicines on NF-κB pathway
| Classifications | Chinese medicines | Models | Mechanisms | References |
|---|---|---|---|---|
| Heat-clearing and dampness-drying medicine | Casticin | RAW264.7 | Repress the NF-κBp65 nucleus translocation | [ |
| Baicalin | DSS-induced colon tissue | Reduce the protein levels of NF-κBp65 and p-NF-κBp65 | [ | |
| UC patients | Decrease ratios of p-NF-κB/NF-κB | [ | ||
| Wogonin | Caco-2 cells | Decrease NF-κB activity | [ | |
| Wogonoside | DSS-induced colon tissues | Inhibit nuclear translocation of NF-κBp65, phosphorylated p65 and NF-κB DNA binding activity | [ | |
| AOM/DSS-induced tumor tissues | Inhibit the protein expression of p-p65 | [ | ||
| THP-1 cells | Suppress NF-κB nuclear translocation | [ | ||
| Berberine | Colonic macrophages and epithelial cells | Inhibit activation of NF-κB | [ | |
| (±)-8-ADC | DSS-induced colon tissues | Reduce phosphor-NF-κBp65 expression; Decrease the NF-κB mRNA expression | [ | |
| IEC6 Cells | Reduce phosphor-NF-κBp65 expression | [ | ||
| Berberine hydrochloride | DSS-induced colonic tissues | Suppress the expressions of phosphorylation of NF-κBp65 | [ | |
| Apocynin | DSS-induced tissues | Reduce the activation of NF-κBp65 | [ | |
| Matrine | TNBS-induced colonic mucosa | Reduce the overexpression of NF-κBp65 | [ | |
| Oxymatrine | TNBS-induced colon mucosa | Down-regulate the expression of NF-κBp65 | [ | |
| Ampelopsis grossedentata | DSS-induced colon tissues | Suppress the NF-κB activation | [ | |
| SM934 | DSS-induced colon tissue | Decrease phosphorylation of NF-κB | [ | |
| Macrophages | Suppress phosphorylation of NF-κBp65; Inhibit NF-κB nuclear translocation | [ | ||
| Artesunate | RAW264.7 cells | Reduce the expression levels of p‑NF‑κB | [ | |
| Tetrandrine | DSS-induced colon tissue | Inhibit the binding activity of NF-κB to DNA | [ | |
| DSS-induced colon tissue | Suppress the NF-κB | [ | ||
| Interior-warming and drying dampness medicine | Aesculin | RAW264.7 cells | Inhibit p-NF‑κBp65 levels in nucleus | [ |
| Total triterpenoids of | DSS-induced colon tissue | Down-regulate the protein expressions of nucleus NF-κBp65, up-regulate the protein expressions of cytosol NF-κBp65 | [ | |
| Cardamonin | RAW264.7 cells | Prevent the nuclear accumulation of NF‑κBp65; Block the translocation of NF‑κBp65 | [ | |
| AA-induced colon tissue | Reduce the levels of NF-κB | [ | ||
| 3,4-Oxo-isopropylidene-shikimic acid | TNBS-induced colon tissues | Decrease NF-κBp65 subunit level | [ | |
| Wu Zhu Yu | DSS-induced colon tissues | Down-regulate the increased phosphorylation levels of NF-κBp65 | [ | |
| Clove | TNBS-induced colon tissue | Down-regulate the expressions of NF-κBp65 | [ | |
| DSS-induced colon tissues | Reduce the expressions of p65-NF-κB | [ | ||
| RAW264.7 macrophages | Decrease the expressions of p65-NF-κB | [ | ||
| DSS-induced colon tissue | Inhibit NF-κBp65 phosphorylation levels | [ | ||
| Galangin | DSS-induced colon tissue | Suppress protein expressions of p-NF-κB; Decrease the accumulation of nuclear NF-κBp65 | [ | |
| Detoxificating and purgative medicine | Parthenolide | DSS-induced colon tissue | Inhibit the phosphorylation of NF-κBp65 | [ |
| HCT116 cells | Block the activation of p65 | [ | ||
| Arctigenin | DSS-induced colonic tissues | Suppress phosphorylation of NF-κBp65 and p65 translocation | [ | |
| Andrographolide derivative AL-1 | TNBS-induced colon tissues | Aattenuate the expression levels of p-p65 | [ | |
| Andrographolide derivative CX-10 | DSS-induced colonic tissue | Reduce the expressions of NF-κB p65 | [ | |
| Brusatol | DSS-induced colon tissue | Attenuate the expression of NF-κBp65 | [ | |
| DSS-induced colon tissues | Suppress the NF-κB activation; Inhibit the phosphorylation of NF-κBp65 | [ | ||
| Total flavonoids of | RAW 264.7 cells | Reduce the phosphorylation of NF-κBp65 | [ | |
| DSS-induced colon tissues | Reduce the activation of NF-κBp65 | [ | ||
| Qing Dai | RAW264.7 cells | Abolish NF‑κBp65 translocation to the nucleus | [ | |
| Indirubin | DSS-induced colon tissues | Reverse DSS-mediated up-regulation of p-NF-κBp65 | [ | |
| Dandelion | DSS-induced NCM460 cell | Decrease the phosphorylation of NF‑κBp65 | [ | |
| DSS-induced colon tissues | Reduce the protein expressions of NF-κBp65 | [ | ||
| Rhubarb-type anthraquinones | RAW264.7 macrophages | Rhein reduce phosphor-NF-κBp65 levels | [ | |
| HT-29 cells | Emodin block NF-κBp65 nuclear translocation | [ | ||
| DSS-induced colitis tissues | Chrysophanol reduce the activation of NF-κBp65 | [ | ||
| Gallic acid | DSS-induced colon tissue | Inhibit the nuclear translocation of NF-κBp65 | [ | |
| RAW264.7 macrophage | Decrease the expression of NF-κBp65 | [ | ||
| Allicin | DSS-induced colonic mucosa | Prevent the inhibition of inducing nuclear translocation of NF-κBp65 | [ | |
| DSS-induced colon tissues | Reduce the level of NF-κBp65 | [ | ||
| Bergenin | RAW264.7 cells | Suppress the nuclear translocation and DNA-binding activity of NF-κBp65; Inhibit the acetylation of NF-κBp65, increase the association of NF-κBp65 and IκBα, and hinder the nuclear translocation of NF-κBp65 | [ | |
| Raw264.7 cells | Inhibit NF-κBp65 nuclear translocation | [ | ||
| Chlorogenic acid | DSS-induced colon mucosa | Reduce the phosphorylation level of NF-κBp65 protein | [ | |
| Blood-activating medicine | Paeonol | CW-2 cells | Reduce NF-κB transactivation | [ |
| Liriodendrin | DSS-induced colon tissues | Suppress the activation of NF-κB pathways; Reduce in phosphorylation of NF-κB | [ | |
| RAW264.7 macrophages | Reduce the phosphorylation of NF-κB | [ | ||
| Shikonin | DSS-induced colon tissues | Reduce the expression of NF-κBp65 | [ | |
| Tetramethylpyrazine | OXZ-induced colitis mucosa | Reduce the rise in NF-κBp65 | [ | |
| Crocetin | TNBS-induced colonic mucosa | Down-regulate the NF-κB | [ | |
| Epicatechin | RAW264.7 cells | Inhibit the activation of NF-κB | [ | |
| Curcumin | Colonic mucosa | Modulate NF-κB activation | [ | |
| Qi-regulating medicine | Norisoboldine | DSS-induced colon tissues | Inhibit phosphorylation, nuclear translocation and DNA-binding activity of NF-κBp65 | [ |
| TNBS-induced colon tissues | Inhibit the NF-κB pathway | [ | ||
| RAW264.7 cells | Inhibit the protein expressions of NF-κB | [ | ||
| Tonifying medicine | HT-29 cells | Reduce the nuclear translocation of NF-κB | [ | |
| Astragalus polysaccharide | DSS-induced colonic tissues | Reduce NF-κB DNA phosphorylation activity | [ | |
| Astragaloside IV | CCD‑18Co cells | Inhibit the phosphorylation of NF‑κBp65 | [ | |
| Licochalcone A | DSS-induced colonic tissues | Reverse the increased expression of p65 NF-κB | [ | |
| Diammonium glycyrrhizinate | AA-induced colonic tissues | Suppress the positive percentage and density of NF-κBp65 | [ | |
| Vanillic acid | DSS-induced colon tissues | Suppress the activation of transcription NF-κBp65 | [ | |
| Paeoniflorin | TNBS-induced colon tissues | Inhibit the expressions of p-NF-κB | [ | |
| The fruit of | AOM/DSS-induced colon tissue | Attenuate the expression of proteins in the NF-κB | [ | |
| Oligonol | DSS-induced colon tissue | Decrease nuclear translocation of NF-κBp65 | [ | |
| RAW264.7 cells | Inhibit NF-κB activation | [ | ||
| Mango extract | CCD-18Co cells | Reduce expression of NF-κB and pNF-κB protein | [ | |
| Astringent medicine | Muscovite | Iodoacetamide-induced colitis tissues | Decrease the activity of NF-κBp65 and reduce the p65 transferred into the nucleus | [ |
| Shan Zhu Yu | Human umbilical vein endothelial cells (HUVECs) | Attenuate NF-κB expression | [ | |
| Macrophages | Inhibit NF-κB activation | [ | ||
| RAW264.7 macrophages | Attenuate the nuclear translocations of NF-κBp65 | [ | ||
| RAW 264.7 cells | Reduce NF-κB activity | [ | ||
| Osthole | DSS-induced colonic tissue | Reduce the expression of NF-κBp65 | [ | |
| Tonifying Qi and activating blood category | Tou Nong San | TNBS-induced colon tissue | Reduce the activation of the NF-κBp65 | [ |
| Heat-clearing and drying dampness category | Shaoyao Decoction | AOM/DSS-induced colonic tissues | Suppress NF-κB activation | [ |
| Qingchang Huashi recipe | HT-29 cells | Reduce the activation of NF-κB | [ | |
| Gegenqinlian Decoction | TNBS-induced colon tissue | Inhibit the activation and translocation of NF-κBp65 | [ | |
| DSS-induced colonic tissues | Decrease the P-NF-κBp65 | [ | ||
| RAW 264.7 cells | Down-regulate the expression of P-NF-κBp65 | [ | ||
| Jianpi Qingchang decoction | DSS‑induced colon tissue | Inhibit the activation of the NF-κB | [ | |
| Modified pulsatilla decoction | OXZ-induced colon tissues | Suppress the activation of the NF-κB | [ | |
| Qing Hua Chang Yin | DSS‑induced colon tissue | Inhibit the expression of the nuclear translocation of NF‑κB | [ | |
| QingBai decoction | DSS‑induced colon tissue | Decrease the protein level of P-NF-κBp65 | [ | |
| Chang-An-Shuan | TNBS-induced colonic tissues | Down-regulate the expression levels of NF-κBp65 | [ | |
| Baishaoqiwu | TNBS-induced colon tissues | Inhibit expression of the NF-ĸBp65 genes | [ | |
| Xie-xin decoction | TNBS-induced colon tissues | Decrease expression of NF-ĸBp65 | [ | |
| Compound sophorae decoction | DSS‑induced colonic tissues | Reduce the level of phospho-NF-κBp65 | [ | |
| Huangkui Lianchang decoction | DSS-induced Colon Tissue | Decrease the NF-B levels | [ | |
| Bawei Xilei powder | UC patients | Decrease the expression of NF-κBp65 | [ | |
| Harmonizing cold and hot category | Ban-xia-xie-xin decoction | DSS-induced colorectums | Inhibition of NF-κBp65 activation | [ |
| Wu-mei-wan | DNCB-induced colonic tissue | Inhibit the NF-κBp65 activity | [ | |
| Warming yang and drying dampness category | Modified ZenWu decoction | DSS-induced colonic tissues | Attenuate the activation of NF-κB and suppress the expression of NF-κBp65 | [ |
| Ping weisan | DSS-induced colon tissues | Reduce phosphorylation of NF-κBp65 | [ | |
| RAW264.7cells | Reduce phosphorylation of NF-κBp65 | [ | ||
| Astringent category | Zhenrenyangzang decoction | TNBS-induced colon tissues | Reduce NF-κB mRNA expression | [ |
Indirect regulatory efficacy of Chinese medicines on NF-κB pathway
| Classifications | Chinese medicines | Models | Mechanisms | References |
|---|---|---|---|---|
| Heat-clearing and dampness-drying medicine | Casticin | RAW264.7 | Down-regulate the phosphorylation of AKT, thus down-regulate the phosphate kinase activity of IKKα/β, thereby failing to phosphorylate IκBα | [ |
| Baicalin | DSS-induced colon tissue | Reduce the protein levels of p-IκB-α, whereas IκB-α protein expression is increased | [ | |
| UC patients | Increase p-STAT6/STAT6 ratio, but decrease ratios of p-STAT4/STAT4 | [ | ||
| Wogonin | Caco-2 cells | Decrease phosphorylation and degradation of IκB; inhibit the expression of TLR4, MyD88 and TAK1 | [ | |
| Wogonoside | DSS-induced colon tissues | Inhibit phosphorylated IκBα | [ | |
| AOM/DSS-induced tumor tissues | Decrease the phosphorylation of IKKα and IκBα, inhibit NF-κB activation via PI3K/Akt pathway | [ | ||
| THP-1 cells | Inhibit phosphorylation of IKKα and IκBα | [ | ||
| Berberine | Colonic macrophages | Inhibit ERK1/2, p38, and JNK activation; inhibit IκB degradation | [ | |
| Colonic epithelial cells | Decrease IκB degradation and ERK1/2 and p38 activation | [ | ||
| Berberine hydrochloride | DSS-induced colonic tissues | Suppress the expressions of phosphorylation of STAT3; inhibit the activation of IL-6/STAT3/NF-κB | [ | |
| Apocynin | DSS-induced tissues | Reduce the activation of STAT3 | [ | |
| SM934 | DSS-induced colon tissue | Decrease phosphorylation of IκB; abrogate the increased phosphorylation of ERK1/2 induced by DSS | [ | |
| Interior-warming and drying dampness medicine | Aesculin | RAW264.7 cells | Suppress the phosphorylation of IκBα | [ |
| Total triterpenoids of | DSS-induced colon tissue | Down-regulate the protein expressions of cytosol PPARγ, tissue p-IKKβ and p-IκBα, decrease the p-IKKβ/IKKβ and p-IκBα/IκBα ratios, up-regulate the protein expressions of nucleus PPARγ, tissue SIRT1 | [ | |
| Cardamonin | RAW264.7 cells | Inhibit phosphorylation and degradation of IκBα; inhibit p38 phosphorylation | [ | |
| 3,4-Oxo-isopropylidene-shikimic acid | TNBS-induced colon tissues | Decrease the change of IκBα expression in the nucleus | [ | |
| Wu Zhu Yu | DSS-induced colonic tissues | Down-regulated the increased phosphorylation levels of IκB | [ | |
| Clove | DSS-induced colon tissues | Reduce the expressions of p-IκB-α | [ | |
| RAW264.7 macrophages | Decrease the expressions of p-IκB-α | [ | ||
| DSS-induced colon tissue | Inhibit IκBα phosphorylation levels; suppress NF-κB due to inhibition of TLR4 | [ | ||
| Galangin | DSS-induced colon tissue | Suppress protein expressions of p-Ikk-βα; increase the expression level of phosphorylation of IκBα in the cytoplasmic fraction | [ | |
| Detoxificating and purgative medicine | Parthenolide | DSS-induced colon tissue | Inhibit IkB protein phosphorylation; block the phosphorylation and degradation of IκBα | [ |
| HCT116 cells | Inhibit the phosphorylation of IkB-α | [ | ||
| Arctigenin | DSS-induced colonic tissues | Suppress phosphorylation of IκBα | [ | |
| Andrographolide derivative AL-1 | TNBS-induced colon tissues | Aattenuate the expression levels of p-IκBα; increase the expression of PPAR-γ | [ | |
| Andrographolide derivative CX-10 | DSS-induced colonic tissue | Reduce the expressions of p-IκBα; increase the expression of IκBα and suppresses the phosphorylated p38MAPK, ERK and JNK | [ | |
| DSS-induced colon tissues | Inhibit the phosphorylation of IκBα | [ | ||
| Total flavonoids of | RAW 264.7 cells | Suppress IκB phosphorylation, and reduce the phosphorylation of MAPK | [ | |
| Qing Dai | RAW264.7 cells | Inhibit IkBα degradation | [ | |
| Indirubin | DSS-induced colon tissues | Reverse DSS-mediated up-regulation of p-IκBα and p-IKKα/β as well as down-regulation of IκBα and IKKα/β | [ | |
| Dandelion | DSS-induced NCM460 cell | Decrease the phosphorylation of Akt | [ | |
| Rhubarb-type anthraquinones | HT-29 cells | Emodin up-regulating the expression of IκB | [ | |
| Macrophages | Chrysophanol inhibit IκBα degradation | [ | ||
| Gallic acid | DSS-induced colon tissue | Attenuate the activation and nuclear accumulation of p-STAT3 (Y705); prevent the degradation of the inhibitory protein IκB | [ | |
| Allicin | DSS-induced colonic mucosa | Inhibit activation and nuclear accumulation of STAT3; prevent the inhibition of protein IκB degradation | [ | |
| Bergenin | RAW264.7 cells | Activate PPARγ, leading to increased expression of SIRT1 | [ | |
| RAW264.7 cells | Inhibit IκB phosphorylation | [ | ||
| Chlorogenic acid | DSS-induced Colon Mucosa | Reduce the phosphorylation level of IκB; improve the expression of ERK1/2, p-ERK, p38, p-p38, JNK, and pJNK proteins of the MAPK/ERK/JNK pathway | [ | |
| Blood-activating medicine | Liriodendrin | DSS-induced colon tissues | Reduce in phosphorylation of Akt; Block the phosphorylation of IκBα | [ |
| RAW264.7 macrophages | Reduce the phosphorylation of IκBα | [ | ||
| Shikonin | DSS-induced colon tissues | Reduce the expression of pSTAT-3 | [ | |
| Tetramethylpyrazine | OXZ-induced colitis mucosa | Restore PPAR-γ expression; reverse increased p38 MAPK phosphorylation | [ | |
| (2)-epigallocatechin-3-gallate | IEC-6 cells | Inhibit the activation of IκB kinase | [ | |
| Curcumin | DSS-induced colonic tissue | Inhibit the activating signals of p38MAPK | [ | |
| Qi-regulating medicine | Norisoboldine | DSS-induced colon tissues | Repress the phosphorylations of p38MAPK and ERK | [ |
| Tonifying medicine | HT-29 cells | Reduce the degradation of IκB | [ | |
| Astragaloside IV | CCD‑18Co cells | Inhibit the phosphorylation of IκB | [ | |
| Licochalcone A | DSS-induced colonic tissues | Reverse the increased expression of IKKα and p-IκB | [ | |
| The fruit of | AOM/DSS-induced colon tissue | Attenuate inflammation, tumor development and progression by down-regulation of expression of STAT3 | [ | |
| DSS-induced colon tissues | Modify p38MAPK and ERK1/2, and then phosphorylating PPARγ, which negatively regulates activation of NF-κB | [ | ||
| Mango polyphenolics | DSS-induced intestinal mucosa | Attenuate the levels of inflammatory markers via suppression of the PI3K/AKT/mTOR signaling pathway, in part through up-regulation of miRNA-126 | [ | |
| Astringent medicine | Ursolic acid | Macrophages | Inhibit the phosphorylation of IKKβ and IκBα; suppress MAPK signaling pathways | [ |
| RAW264.7 macrophages | Block the IκBα phosphorylation and degradation of IκBα; suppression of MAPK activation | [ | ||
| Osthole | DSS-induced colonic tissue | Reduce the expression of p-IκBα and increase IκBα expression | [ | |
| RAW 264.7 cells | Reduce the phosphorylation of the MAPK/p38 protein; Facilitate a full recovery of the degradated IκBα protein | [ | ||
| Tonifying Qi and activating blood category | Shen Ling Bai Zhu San | DSS-induced colonic tissue | MAPK and NF-κB pathways share crosstalk | [ |
| Tou Nong San | TNBS-induced colon tissue | Inhibit p65 mainly by inhibiting the phosphorylation of IKK | [ | |
| Heat-clearing and drying dampness category | Gegenqinlian decoction | DSS-induced colonic tissues | Decrease the P-IκB | [ |
| RAW 264.7 cells | Inhibit the degradation of IκB | [ | ||
| Jianpi Qingchang decoction | DSS‑induced colon tissue | Increase the expression of IκB | [ | |
| Qing Hua Chang Yin | DSS‑induced colon tissue | Inhibit the expression of the phosphorylation of IκB | [ | |
| Caco-2 cells | Suppress the phosphorylation of JAK1, JAK2 and STAT3 | [ | ||
| QingBai decoction | DSS-induced colon tissue | Strengthen mucus barrier through inhibiting p‐ERK and Notch signaling | [ | |
| Chang-An-Shuan | TNBS-induced colonic tissues | Reduce the levels of p38 and p-AKT proteins | [ | |
| Compound sophorae decoction | DSS‑induced colonic tissues | Suppress the activation of STAT3 | [ | |
| Huangkui Lianchang decoction | DSS-induced Colon Tissue | Decrease the IκBα and p-IκBα levels | [ | |
| Warming yang and drying dampness category | Modified ZenWu decoction | DSS-induced colonic tissues | Lessen the degradation of IκBα | [ |
| Ping weisan | DSS-induced colon tissues | Reduce phosphorylation of IκBα | [ | |
| RAW264.7cells | Reduce phosphorylation of IκBα | [ | ||
| Astringent category | Zhenrenyangzang decoction | TNBS-induced colon tissues | Attenuate the protein expression of IκB-α subunit and phosphorylated p38MAPK (p-p38MAPK) | [ |
Fig. 1The schematic diagram of Chinese medicines direct and indirect regulating NF-κB pathway in UC treatment